Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ANGION BIOMEDICA CORP.

(ANGN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Angion Biomedica Corp. is a late-stage biopharmaceutical company. The Company focuses on discovery, development and commercialization of small molecule therapeutics to address acute organ injuries and fibrotic diseases. The CompanyÔÇÖs lead product candidate is ANG-3777. Its pipeline includes ANG-3070, rho kinase 2 (ROCK2), and CYP11B2. Its ANG-3777 is a hepatocyte growth factor (HGF) mimetic it is evaluating in multiple acute organ injuries and related indications, including acute kidney injury (AKI) and injuries to other organs, such as the lungs, central nervous system (CNS) and heart. It is also evaluating ANG-3777 for indications within acute lung injury (ALI), with focus on acute respiratory distress syndrome (ARDS), as well as acute CNS injuries. The CompanyÔÇÖs other programs are for the treatment of fibrotic diseases, ANG-3070, a tyrosine kinase inhibitor (TKI), and inhibitor of rho kinase 2 (ROCK2).

Number of employees : 53 people.
Sales per Business
20192020Delta
Novel Small Molecule Therapeutics1.49100%2.88100% +93.68%
USD in Million
Sales per region
20192020Delta
United States1.49100%2.88100% +93.68%
USD in Million
Managers
Name Title Age Since
Jay R. Venkatesan, Dr. President, Chief Executive Officer & Director 49 2018
Greg S. Curhan Chief Financial Officer 59 2020
Itzhak D. Goldberg, Dr. Executive Chairman & Chief Scientific Officer 72 2018
John F. Neylan, Dr. Chief Medical Officer & Senior Vice President 68 2018
Jennifer J. Rhodes Secretary, Chief Compliance Office & Senior VP 50 2020
Allen R. Nissenson, Dr. Independent Director 74 2020
Gil S. Omenn, Dr. Independent Director 79 2020
Karen J. Wilson Independent Director 58 2020
Victor Ganzi Independent Director 74 2018
Elisha Y. Goldberg Director-Business Development - -
Members of the board
Name Title Age Since
Itzhak D. Goldberg, Dr. Executive Chairman & Chief Scientific Officer 72 2018
Jay R. Venkatesan, Dr. President, Chief Executive Officer & Director 49 2018
Allen R. Nissenson, Dr. Independent Director 74 2020
Gil S. Omenn, Dr. Independent Director 79 2020
Karen J. Wilson Independent Director 58 2020
Victor Ganzi Independent Director 74 2018
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 30,437,426 18,133,057 59.6% 0 0.0% 59.6%
Shareholders
NameEquities%
Eisa Abc LLC 2,740,978 9.15%
Schuler Family Foundation 2,587,595 8.64%
Vifor Pharma AG 1,995,643 6.66%
Itzhak D. Goldberg 1,720,068 5.74%
Jay R. Venkatesan 1,639,257 5.47%
Victor Ganzi 1,261,319 4.21%
BVF Partners LP 1,071,297 3.58%
Park West Asset Management LLC 1,041,776 3.48%
The Vanguard Group, Inc. 864,589 2.89%
Franklin Advisers, Inc. 615,000 2.05%
Brand Portfolio
In partnership withAllbrands.markets
More brands of Angion Biomedica Corp.
Sector Other Biotechnology & Medical Research